comparemela.com

Christophert Ritchlin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Teasing Apart Multiple Biologic Failure in Psoriasis, PsA

Tough-to-treat psoriasis remains a challenge despite newer therapies . Why do we still have this sub-population of patients who seem to be refractory?

San franciscoUnited statesChristophert ritchlinTrex bioWilson liaoAmerican college of rheumatologySkin treatment centerUniversity of rochesterMusculoskeletal researchUniversity of californiaNational psoriasis foundationNational psoriasisSkin treatmentPsoriasis areaSeverity indexCorevitas psoriasis registry

Bimekizumab Demonstrates Sustained Efficacy in bDAMRD-Naïve Patients with PsA

At week 52, patients in the bimekizumab cohort demonstrated sustained clinical responses, which were consistent with results reported at week 16.

Christophert ritchlinAmerican college of rheumatologyUniversity of rochesterImmunology rheumatology divisionClinical immunology research unitHealth assessment questionnaireUniversity of rochester medical schoolRochester medical centerRochester medical schoolRheumatology divisionAmerican collegePsoriasis areaSeverity indexFunctional assessmentChronic illness therapyHealth assessment questionnaire disability index

PsA Prevention Study With Biologics Contradicts Prior Findings

Differing patient selection criteria and other biases may be why results from a new study contradict those from three prior studies, suggesting the need for prospective studies.

University of pennsylvaniaUnited statesElana meerJoelm gelfandChristophert ritchlinOptuminsights electronic health record databaseUniversity of rochesterNational psoriasis foundationOptuminsights electronic health recordLikely playsLarge roleRetrospective psa studyBiologic therapyPsoriatic arthritisProstate carcinomaAlignant prostate neoplasm

vimarsana © 2020. All Rights Reserved.